4D Molecular Therapeutics Net Income

4D Molecular Therapeutics (FDMT) currently reports a net income of $-180M as of June 2026. That compares with $-200M in the prior-year period — up 8.7% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore 4D Molecular Therapeutics's net income history and peer comparisons.

4D Molecular Therapeutics's net income increased from $-200M to $-180M — a 8.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

4D Molecular Therapeutics's net income of $-180M is lower than the Healthcare sector average of $16B. That is roughly 101.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

4D Molecular Therapeutics reported $-180M in net income as of June 2026. That compares with $-200M in the prior-year period — up 8.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-180M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for 4D Molecular Therapeutics, and consider following FDMT for alerts when major investors trade the stock.